215
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE
“
MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS
”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
GOVERNMENT SUPPORT MEASURES FOR API MANUFACTURERS IN RUSSIA
AND ABROAD
Smirnov A.S.
Saint Petersburg State University of Chemistry and Pharmacy, Saint Petersburg,
Russian Federation
e-mail: smirnov.anatolij@spcpu.ru
https://doi.org/10.5281/zenodo.17332962
Relevance:
the strategic importance of the development of the active pharmaceutical
substances (API) market for the sustainability of Russian healthcare and reducing import dependence
in the context of global economic and geopolitical challenges. High technological and economic
barriers to API production require effective government support and innovation measures. An
analysis of the domestic market and the foreign experience of leading countries will allow us to
identify successful incentive models, increase the competitiveness of domestic manufacturers and
ensure the long-term development of the pharmaceutical industry in Russia.
Purpose of the study:
to conduct a comprehensive analysis of the active pharmaceutical
substances (API) market in Russia for the period 2014-2024, identify key trends, problems and
challenges of production, as well as evaluate the effectiveness of government support measures. In
addition, the research is aimed at studying and comparing foreign experience in stimulating the
industry in leading countries of the world in order to identify successful development models that can
be adapted to increase the competitiveness and sustainability of the Russian pharmaceutical sector.
Materials and methods:
pharmaceutical market analysis data, Rosstat statistics, reports from
the Ministry of Industry and Trade, and analytical data from research companies DSM and RNC.
Comparative analysis methods were applied, which made it possible to compare national strategies
according to key criteria: the volume of investments, the number of projects supported, the degree of
localization of production and the pace of industry growth.
Results:
since 2014, the Russian industry has faced unprecedented sanctions pressure and a ban
on the import of medicines and APIs, as well as the flight of foreign manufacturers from the market,
which has caused short-term shortages of vital and essential medicines (VED), which has been
particularly acute since 2022. The introduction of GMP requirements led to the closure of some
production facilities and a decrease in the share of domestic substances to 16% in 2019. At the same
time, the economy is showing GDP growth, pointing to the potential of the industrial complex.
An analysis of the international experience of 2022-2025 has shown that targeted government
support measures — subsidies, tax incentives, direct financing and infrastructure development —
significantly stimulate the production and export of APIs, reducing dependence on imports.
Successful cases from India, the USA, France, Germany and South Korea allow us to develop
recommendations for the effective development and strengthening of the Russian pharmaceutical
sector.
The presented data indicate that the effectiveness of measures depends on the structure of the
industry, the level of coordination and the stability of financing. In countries with integrated support
(India, France, Hungary), localization of production is accelerating, while in the USA and Germany
the processes remain fragmented and require long-term support. Countries that are building up
infrastructure and institutional mechanisms at the same time as financial incentives are demonstrating
higher rates of expansion and utilization of production capacities.
216
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE
“
MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS
”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
Conclusions:
in order to ensure the sustainability and development of the Russian
pharmaceutical industry, it is necessary to implement effective government support measures based
on international experience, which will increase local production of APIs, reduce dependence on
imports and ensure strategic security in the healthcare sector.
